SkyCell has partnered with Korean Air Cargo as the data-driven temperature-controlled container specialist focuses on business development in Korea.
The partnership follows SkyCell’s recent launch of a service centre in Seoul and the appointment of Charlie Cho as Business Development Director for Korea as of January 1.
The partnership comes at a crucial point with the increase in demand for COVID-19 vaccines and treatments this year.
Cold-chain maintenance for vaccine transportation is a significant challenge for the global logistics industry, and together SkyCell and Korean Air ensure these lifesaving medicines reach patients timely and in pristine condition.
Eum, Jae Dong, Senior Vice President and Head of Cargo Business Division at Korean Air commented: “We were attracted to the fact that Skycell has recently opened a new station in Seoul, and that its sustainable and self-recharging hybrid containers are in line with our green management policy.
“Through this agreement, we are pleased to expand our service offering to the pharma industry with SkyCell’s hybrid containers and provide our clients with a safe and sustainable solution to protect sensitive products.
Chiara Venuti, Director of Business Development and Head of Airline Partnerships at SkyCell said: “We at SkyCell are proud to partner with Korea Air and ensure vital medicine reach their destinations fast and without spoilage.
“As we navigate this difficult time together we are committed to helping our partners achieve their goals, and ensure these vital medicines are transported in a safe and timely manner.
“When shipping vital pharmaceutical products, there is no room for error, and we are happy to support Korean Air to ship pharmaceuticals in a sustainable way.”
The Korean pharmaceutical industry has seen rapid growth over the last five years, growing at an annual rate of around 7%, led by locally developed novel therapies and biosimilars – almost three times faster than the manufacturing sector. Exports of Korean pharmaceuticals grew by 11.2% last year to over $5.19bn.
SkyCell’s hybrid containers allow pharma companies to optimise supply chains using data to predict and control risk. Using over three-quarters of a billion data-points on factors like temperature, location, and time, it enables a market-leading and audited failure rate of less than 0.1%, while reducing CO2 emissions by almost half.
Last year, Korean Air was awarded the IATA Centre of Excellence for Independent Validators (CEIV) Pharma certification.
